Skip to main content

IV Fluid Bags Market Size Report 2021-2028 | Share, Growth, Trends, Competitive Landscape, Revenue, Forecast Analysis

Key Companies in IV Fluid Bags Market are Braun Melsungen AG, Baxter, ICU Medical Inc., Sippex IV bag, Fosmo Med, Fresenius Kabi AG, Polifarma

Pune, India, Oct. 13, 2021 (GLOBE NEWSWIRE) — The global IV Fluid Bags Market size is set to gain traction due to increased prevalence of disease and rising geriatric population around the world, observes Fortune Business Insights™ in its report, titled “IV Fluid Bags Market-2021-2028”.

The IV is given to patients suffering from chronic diseases such as cancer, diabetes or a person going through any surgical procedure. Thus due to increased demand investors are investing in IV therapy. For instance, in May 2019, Braun Melsungen AG invested USD 1 billion for advanced IV therapy in the U.S. health infrastructure. These aforementioned factors are thus expected to drive the market during the forecast period.


Get Sample PDF Brochure: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/intravenous-iv-fluid-bags-market-102036


List of Key Players in IV Fluid Bags Market:

  • Braun Melsungen AG
  • Baxter
  • ICU Medical Inc.
  • Sippex IV bag
  • Fosmo Med
  • Fresenius Kabi AG
  • Polifarma

COVID-19 Pandemic:

The outbreak of the COVID-19 pandemic increased demand for IV therapies, as serious patients were given medications through IVs. In addition, increased plasma donation also increased its demand. However, the market suffered a moderate disruption, as non-emergency surgeries were at a halt. The market is expected to flourish in the upcoming years.

Segments-

By fluid type, the market is segmented into normal saline, dextrose, ringer’s lactate, vitamins, and others. Based on application, it is segmented into clinical and wellness. By end-user, it is divided into hospital, hydration clinics, home care settings, and others. Lastly, in terms of geography, the market is categorized into North America, Europe, Asia Pacific, Latin America and the Middle East & Africa.


To get to know more about the short-term and long-term impact of COVID-19 on this market,

Please Visit: https://www.fortunebusinessinsights.com/intravenous-iv-fluid-bags-market-102036


Report Coverage-

The report aims to analyze the industry by considering contributions, prospects, and growth trends. It presents detailed profiles of every key player operating in the market to analyze their core competencies in each segment. Apart from that, it ensures to help our clients better understand the competitive developments, such as mergers & acquisitions, new product launches, joint ventures, and collaborations.

Drivers & Restraints

Increasing Prevalence of Chronic Diseases to Drive the Market

The rising prevalence of diseases is anticipated to drive the IV Fluid Bags Market growth. For instance, according to a report by the American Diabetes Association in the year 2015, around 30.3 million people in the U.S were suffering from diabetes. Additionally, the technological advancements and innovation done in the IV are also contributing to the market, as now PVC-free bags are used. The new IV bags are made of non-latex materials, and these are safe and are more accurate as compared to the PVC ones. 

On the other hand, the risk of several other infectious diseases associated with IV is the major market constraint.


Have Any Query? Ask Our Experts:

https://www.fortunebusinessinsights.com/enquiry/queries/intravenous-iv-fluid-bags-market-102036


Regional Insights

North America to Dominate Backed by Rising Number of Population

North America is expected to hold the highest IV Fluid Bags Market share due to the large population in the region suffering from chronic diseases, such as cancer, diabetes, and kidney disease. For instance, as per the CDC report, nearly 4.9 million adults in the U.S are diagnosed with kidney stones.

Europe is also expected to dominate the market due to favorable reimbursement policies launched by the government and the presence of prime healthcare infrastructure in the region.

Competitive Landscape

Key Players to Focus on New Launches to Intensify Competition

The market is consolidated by the presence of major companies that are striving to maintain their position by focusing on new launches. For instance, in July 2019, Baxter launched Myxredlin. It is U.S FDA approved and first and only ready to use insulin IV infusion. Moreover, other key players are adopting proactive strategies such as mergers, and facility expansion to favor the market’s growth in the forthcoming years.

Industry Development

  • June 2019:Eurolife Healthcare based in India launched high quality Intravenous IV products – Discport and Lifeport. These are smart intravenous infusion made with the best of the latest technology. These reduces the chances of any infections apart from ease of use.


Ask for Customization of this Report:

https://www.fortunebusinessinsights.com/enquiry/customization/intravenous-iv-fluid-bags-market-102036


About Us:

Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.


Contact Us:

Fortune Business Insights™ Pvt. Ltd.

308, Supreme Headquarters,

Survey No. 36, Baner,

Pune-Bangalore Highway,

Pune – 411045, Maharashtra, India.


Phone:

US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Email: sales@fortunebusinessinsights.com

LinkedIn: https://www.linkedin.com/company/fortune-business-insights

Facebook: https://www.facebook.com/FortuneBusinessInsightsPvtLtd

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.